ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.591
EU - Europa 3.747
AS - Asia 3.489
SA - Sud America 44
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 12
Totale 22.930
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.542
SG - Singapore 1.478
HK - Hong Kong 1.092
SE - Svezia 995
GB - Regno Unito 743
CN - Cina 637
IT - Italia 611
DE - Germania 361
BG - Bulgaria 353
FI - Finlandia 158
UA - Ucraina 83
TR - Turchia 68
FR - Francia 67
ID - Indonesia 64
LT - Lituania 51
AT - Austria 46
IE - Irlanda 46
CA - Canada 45
NL - Olanda 40
CZ - Repubblica Ceca 38
BE - Belgio 35
IN - India 30
RO - Romania 26
JP - Giappone 18
RU - Federazione Russa 18
MY - Malesia 17
CL - Cile 16
EG - Egitto 16
ES - Italia 16
VN - Vietnam 16
BR - Brasile 15
IR - Iran 15
A2 - ???statistics.table.value.countryCode.A2??? 14
AU - Australia 11
CH - Svizzera 9
MK - Macedonia 9
SA - Arabia Saudita 9
NO - Norvegia 7
PH - Filippine 7
GR - Grecia 6
PL - Polonia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
TH - Thailandia 5
TN - Tunisia 5
AR - Argentina 4
BD - Bangladesh 4
DK - Danimarca 4
IL - Israele 4
MD - Moldavia 4
PE - Perù 4
PK - Pakistan 4
BZ - Belize 3
EC - Ecuador 3
ET - Etiopia 3
KH - Cambogia 3
KR - Corea 3
PT - Portogallo 3
ZA - Sudafrica 3
BY - Bielorussia 2
CY - Cipro 2
KE - Kenya 2
SS - ???statistics.table.value.countryCode.SS??? 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
CO - Colombia 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MX - Messico 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 22.930
Salva come PNG Salva come JPEG
Città #
Fairfield 2.372
Chandler 2.080
Santa Clara 1.518
Ashburn 1.361
Singapore 1.242
Hong Kong 1.083
Nyköping 857
Woodbridge 847
Houston 745
Wilmington 737
Seattle 676
Cambridge 624
Ann Arbor 473
San Diego 459
Princeton 372
Sofia 353
Southend 344
New York 163
Dearborn 152
Modena 146
Helsinki 144
Jacksonville 139
London 136
Beijing 129
Bremen 86
Shanghai 81
Jakarta 64
Norwalk 56
Izmir 48
Kilburn 44
Vienna 43
Dublin 42
Grafing 41
Des Moines 39
Augusta 37
Brussels 34
Brno 33
San Mateo 33
Bologna 32
Eugene 30
Milan 29
Chiswick 28
Munich 26
Toronto 26
Paris 25
Redwood City 22
Los Angeles 20
Amsterdam 19
Falls Church 19
Guangzhou 19
Hounslow 19
Leawood 19
Rome 19
Reggio Emilia 18
Phoenix 17
Prescot 15
Timisoara 15
Chicago 14
Dong Ket 14
San Francisco 14
Dallas 12
Hangzhou 12
Boardman 10
São Paulo 10
Wuhan 10
Naples 9
Acton 8
Boydton 8
Buffalo 7
Islington 7
Jiaxing 7
Tokyo 7
Washington 7
Florence 6
Frankfurt am Main 6
Fremont 6
Istanbul 6
Nanjing 6
Parma 6
Southwark 6
Turin 6
Andover 5
Chongqing 5
Clearwater 5
Collegeville 5
Jinan 5
Las Vegas 5
Madrid 5
Padova 5
Rimini 5
Rumah 5
Torino 5
Wandsworth 5
Ardabil 4
Carpi 4
Cascina 4
Hiroshima 4
Melbourne 4
Montreal 4
Olomouc 4
Totale 18.542
Salva come PNG Salva come JPEG
Nome #
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 282
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 218
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 218
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 206
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 203
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 203
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 202
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 198
Missed treatment in an Italian HBV infected patients cohort: HBV RER 195
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 194
Treatment of nonalcoholic steatohepatitis in adults: present and future 190
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 180
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 178
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 174
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 172
From current status to optimization of HCV treatment: Recommendations from an expert panel 168
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 166
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 157
Update on Alcohol and Viral Hepatitis 149
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 149
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 145
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 143
Gross pathologic types of hepatocellular carcinoma in Italy. 141
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 140
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 140
Non-alcoholic steatohepatitis and liver transplantation 139
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 135
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 132
Characteristics of hepatocellular carcinoma in Italy 129
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 129
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 126
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 126
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 123
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 113
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 112
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 105
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 105
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 100
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 95
Adaptive response in Hepatitis B virus infection 94
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 87
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 87
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 85
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 83
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 83
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 83
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 83
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 83
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 82
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 81
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 81
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 81
Juvenile hemocromatosis associated with pathogenetic mutations of adult hemocromatosis genes 80
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis 79
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 79
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 78
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 78
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 78
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 78
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 77
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection 77
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 77
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 76
Chronic hepatitis B: Are we close to a cure? 76
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 76
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 75
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 75
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 75
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 75
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 75
Liver transplantation for patients with alcoholic liver disease: an open question 74
Stem cell mobilization and collection in patients with liver cirrhosis 74
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 74
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 73
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 72
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 72
Alcohol and viral hepatitis: a mini-review 72
Global multi-stakeholder endorsement of the MAFLD definition 71
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 71
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels 71
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 71
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 71
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 71
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 70
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 70
Hepatitis B virus and immune response 69
Clinical and serological profile of primary biliary cirrhosis in men 69
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 69
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 68
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 68
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 68
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 67
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival 66
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 66
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 66
DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods 66
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 65
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 65
Stem cell therapy for human liver cirrhosis: a cautious analysis of the results 65
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 65
Totale 10.736
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.661
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020992 0 0 0 0 132 236 220 128 130 52 61 33
2020/20213.695 89 43 66 159 155 161 285 158 1.347 142 954 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/20253.166 463 84 65 962 1.592 0 0 0 0 0 0 0
Totale 23.427